Kornimate/medical-research-clean huggingface dataset:
aortic balloon counterpulastion in myocardial infarction related shock

Conditions: Myocardial Infarction; Cardiogenic Shock

Summary: the role of intra aortic balloon counterpulsation in patients experiencing acute myocardial infarction with shock is not established. we hypothesised that use of such a device would lead to improved outcomes in these patients.

patients undergoing percutaneous coronary intervention (pci) for acute myocardial infarction (ami) with cardiogenic shock (cs) are often treated with intra-aortic balloon pump counterpulsation (iabp) although the evidence to support this is limited. we conducted a prospective, randomised clinical trial, of iabp as an addition to pci centred therapy, in patients with ami complicated by cs. 45 patients with ami and cs undergoing pci were randomised to care with or without iabp. over 4 days, apache ii scores, haemodynamic parameters, inflammatory markers and bnp levels were collected to assess the impact of iabp treatment on cs triggered multi organ dysfunction syndrome (mods).

Eligibility criteria:
inclusion criteria: * acute myocardial infarction * cardiogenic shock exclusion criteria: * absent peripheral pulses * mechanical complications of myocardial infarction

Keywords: myocardial infarction cardiogenic shock systemic inflammatory response syndrome percutaneous coronary intervention aortic balloon counterpulsation
out-of hospital resuscitation study

Conditions: Ventricular Fibrillation; Asystoly; Resuscitation

Summary: sudden cardiac arrest is one of the most common causes of death in industrial countries. the main objective of this study is to built up a register of all out-of hospital resuscitation in a defined area. according to this register, it is possible to evaluate for example predictors of survival to improve training and organisation of prehospital resuscitations.


Eligibility criteria:
inclusion criteria: * out of hospital cardiac arrest exclusion criteria: * none
lidocaine spray use on patients comfort in undergoing bladder catheterization

Conditions: Urinary Catheterization As the Cause of Abnormal Reaction of Patient, or of Later Complication, Without Mention of Misadventure At Time of Procedure

Summary: bladder catheterization is a procedure frequently performed in emergency departments and may cause symptoms such as pain and discomfort in patients. this study hypothesizes that lidocaine spray application will improve patient compliance and comfort from the outset and facilitate smoother medical procedures. in our prospective, case-controlled study, the patients were divided into two groups: group l (lidocaine) and group p (placebo). pain conditions after bladder catheterization were evaluated at 0 minutes (during the procedure) and 15, 30 and 60 minutes after the procedure. face legs arm cry consolability pain scale (flacc) and wong-baker pain scales were used. all time periods in group l, flacc score and wang baker scores were found to be statistically significantly lower.the differences between the first measurement and the measurements at 15-30-60 minutes of the flacc score were found to be significantly higher in group p than in group l. as a result, we recommend that lidocaine spray be applied before urinary catheter insertion. this study showed that lidocaine spray increased patients\&#39; sleep at the end and reduced the feeling of restlessness by reducing pain.


Eligibility criteria:
inclusion criteria: the study included male patients over 18 years old, without trauma, with spontaneous urine output, and who were oriented and cooperative. - exclusion criteria: exclusion criteria were patients under 18 years old, female patients, patients with trauma, patients with globe vesicale (due to the need for rapid bladder catheterization), patients with anatomical variations, patients with urethral-bladder outlet problems preventing catheterization, and patients who refused to participate in the study. -

Keywords: bladder catheterization pain control lidocaine spray patient comfort
nutritional prevention of exertional muscle dysfunction

Conditions: Muscle Dysfunction; Exertional Rhabdomyolysis; Muscle Strength

Summary: the investigators want to find out whether a choline supplement can protect muscle health in young men with very common genetic vulnerabilities. men, who respond to a brief, but intense set of arm exercise and have a common genetic profile, will be asked to use a choline supplement for three weeks and a placebo for three weeks. before the begin of the supplementation study and after 3 and 6 weeks the investigators will test response to the exercise challenge and ask that all consumed foods are recorded.

an initial screening questionnaire will determine general eligibility. the investigators will screen white young males with low to moderate choline intake (\<450 mg/d) for ck response to exercise (high/low) by having them do intense eccentric exercise (12 elbow flexor contractions of non-dominant arm with dumbbell at 100% maximal lift capacity) and then 72 hours (3 days) later draw 250 μl capillary blood by finger stick for ck, metabolomic and genetic measurements. the investigators plan to recruit 30 ck responders with an 1958 a allele of the methylenetetrahydrofolate dehydrogenase 1 (mthfd1), which is present in about 60% of caucasian males. all participants will be asked to complete on three days 24-hour diet interviews with an online automated program provided by the national cancer institute. participants of the intervention study will also have to be complete interviews on the final three days of the two intervention periods the recruited candidates will do an initial exercise challenge with no intervention, then a second challenge after three weeks with the first supplement (randomized choline or placebo), then a third challenge after another three weeks with the complementary second supplement (choline if they had placebo first, placebo if they had choline first). samples identified only by code will be stored indefinitely at the unc nutrition research institute to permit the analysis of additional genetic markers related to muscle health and choline metabolism when the capacity for the analysis of such markers becomes available. such analyses may be carried out at the university of north carolina nutrition research institute (unc nri) or at external laboratories providing the service for the pi. samples will be destroyed once no such additional analyses are intended or feasible anymore or if the investigators do not continue this research. storage of the samples is not optional.

Eligibility criteria:
inclusion criteria: * caucasian * choline intake less than 450 mg * exertional muscle dysfunction * susceptible genetic profile exclusion criteria: * severe chronic illness * limited range of arm motion * required use of prescription medication * required use of dietary supplements

Keywords: muscle muscle dysfunction choline exercise exertional rhabdomyolysis rhabdomyolysis
pain education in chronic low back pain

Conditions: Low Back Pain; Rehabilitation; Pain

Summary: the pain neuroscience education (pne) aims to reconceptualize pain from a marker of tissue damage to a marker of the perceived need to protect body tissue. the purpose of this study is to verify the long-term efficacy (6 months) of a pain education treatment in patients with chronic low back pain, compared to a conventional treatment.


Eligibility criteria:
inclusion criteria: * age over 18 * patients with low back pain of musculoskeletal origin for at least 3 months * patients free from nsaid and/or opioid analgesic therapy for at least 1 month * years of education: over 13 * italian mother-tongue exclusion criteria: * presence of neurological symptoms on provocative tests * recent surgical procedure * patients suffering from fibromyalgia or other rheumatological pathology * psychiatric pathologies
intrathecal morphine for inguinal hernia repair.

Conditions: Inguinal Hernia; Nausea; Vomiting; Pruritus; Postoperative Pain

Summary: the aim of this study was to compare the effects of two different doses of intrathecal morphine (0.1 mg and 0.4 mg) combined with 7.5 mg of heavy bupivacaine on postoperative block regression times, postoperative analgesia and the severity of side effects, for inguinal hernia repairs.

the purpose of this study was to compare spinal anesthesia with low dose heavy bupivacaine combined with 0.1 mg or 0.4 mg of morphine in inguinal hernia repair surgeries. anesthesia onset time (sensory and motor blocks) as well as postoperative recovery (first mobilisation, first voiding) time were compared. also the postoperative pain management and side effects (nausea, vomiting and pruritus) were assessed.

Eligibility criteria:
inclusion criteria: * american society of anaesthesiology physical status i-ii patients * aged 18-65 years * undergoing elective unilateral open inguinal hernia repair surgery exclusion criteria: * contraindications to spinal anesthesia * central or peripheral neuropathies * severe respiratory or cardiac diseases * chronic analgesic use * history of substance abuse * allergy to local anesthetics

Keywords: spinal anaesthesia morphine postoperative analgesia vomiting
peeled internal limiting membrane reposition

Conditions: Macular Holes

Summary: macular hiatus (mh) refers to a tissue defect in the photoreceptor cell layer of the inner boundary membrane of the optic disc in the macular region. among them, idiopathic macular hiatus (imh) is more common in people over 60 years old and is a common eye disease. with the aging of society, the number of patients increases, and it severely damages the patients' vision and life quality. previously, the conventional surgical approach for treating mh was vitrectomy combined with inner limiting membrane (ilm) peeling. although the closure rate of mh is high, many damages to the morphology and function of the ilm peeled area have been found. our team firstly report a novel technique of peeled ilm reposition. compared to traditional ilm peeling, the novel technique peeled ilm reposition maintains the integrity of internal retina by "pull" back the ilm flap. the previous pilot clinical study suggests that the novel technique peeled ilm reposition surgical intervention can achieve better morphology and functional prognosis. however, there is currently a lack of larger sample size prospective randomized controlled studies to further clarify the clinical efficacy of this new surgical technique in treating imh. this study aims to conduct a single center, prospective, and randomized controlled study, combined with previous work, to analyze the efficacy of this novel technique peeled ilm peeling in the treatment of imh. we hypothesize that this novel technique can achieved better morphological and functional prognosis compared to traditional ilm peeling.


Eligibility criteria:
inclusion criteria: 1. the patients are diagnosed as mh with a diameter ≤ 600 µm by optical coherence tomography. 2. age ranges from 50 to 80 years. 3. do not participate in other clinical studies. 4. agree to sign an informed consent form with good compliance. exclusion criteria: 1. traumatic macular hole. 2. combined with serious epiretinal membrane. 3. combined with diabetic retinopathy, hypertensive retinopathy. 4. combined with other ocular diseases, such as keratitis，uveitis，retinal vasculitis. 5. spherical equivalent ≥ -6.0 diopters or axial length ≥ 26 mm. 6. history of intraocular surgery. 7. presence of staphyloma. 8. other ocular diseases that influence macular microstructure or visual function.
open-label, dose-escalation study of pemigatinib in subjects with advanced malignancies - (fight-101)

Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN

Summary: the purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. this study will have three parts, dose escalation (part 1), dose expansion (part 2) and combination therapy (part 3).


Eligibility criteria:
inclusion criteria: 1. male or female subjects, age 18 years or older on day of signing consent 2. part 1: any advanced solid tumor malignancy; part 2: subjects with squamous non-small cell lung cancer, cholangiocarcinoma/gastric cancer, urothelial cancer, breast/endometrial cancer, multiple myeloma, or mpns that have a tumor or malignancy that has been evaluated and confirmed to harbor genetic alterations in fgf or fgfr genes. a subject's fibroblast growth factor (fgf) or fibroblast growth factor receptor (fgfr) alteration may be based on local or central laboratory results. part 3: dose finding: subjects with solid tumor malignancies who qualify for combo therapy; dose-expansion: fgf/fgfr+ subjects qualified to receive combo therapy 3. has progressed after prior therapy and there is no further effective standard anticancer therapy available (including subject refuses or is intolerant) 4. life expectancy \> 12 weeks 5. eastern cooperative oncology group (ecog) performance status: * part 1: 0 or 1 * part 2 and 3: 0, 1, or 2 exclusion criteria: 1. treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 21 days or 5 half-lives before first dose of study drug 2. prior receipt of a selective fgfr inhibitor 3. history of a calcium/phosphate homeostasis disorder 4. history and/or current evidence of ectopic mineralization/calcification 5. current evidence of corneal disorder/keratopathy 6. has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac function parameters outside protocol-defined range 7. prior radiotherapy within 2 weeks of study treatment

Keywords: alterations in fgf or fgfr squamous non-small cell lung cancer gastric cancer urothelial cancer endometrial cancer multiple myeloma mpn
simultaneous recording of cognitive and motor functions after stroke

Conditions: Stroke

Summary: aim: to assess whether a cognitively demanding dual-task has greater impact on manual dexterity in chronic stroke patients than in healthy subjects. methods: a visuomotor force-tracking task, combining grip force and oculomotor recordings, will be applied in chronic stroke patients with mild-moderate hemiparesis without clinical cognitive impairments and in age-comparable healthy subjects. the dual-task includes avoiding visual distractors and mental addition of numbers. dual-task effect is calculated as difference in force control accuracy (dual minus single-task) and as difference in saccade rate (addition of numbers minus visual distractors).


Eligibility criteria:
inclusion criteria: * \> 18 years old * first symptomatic stroke more than 3 months ago * box and blocks test score \< 52 * mini mental state examination test \> 25 exclusion criteria: * psychiatric disease * risk of pregnancy * history of previous stroke * disability that may interfere with the performance of tasks
yoga breathing for fatigue in patients undergoing chemotherapy

Conditions: Breast Cancer

Summary: the purpose of this study is to determine the feasibility and efficacy of yoga breathing techniques to manage fatigue and other cancer-related side effects, in cancer patients undergoing chemotherapy.

fatigue is the most common complaint among cancer patients. this pilot study will evaluate the effects of pranayama (ancient yoga breathing techniques) on fatigue and quality of life among 30 patients undergoing chemotherapy, on an every 2, 3, or 4 week schedule, with a fatigue score of at least 4 on a scale of 0 (none) to 10 (most). patients will be randomized to either pranayama or wait-list control. the pranayama group will learn and practice 3 breathing techniques on a daily basis. the study period will occur during 2 consecutive cycles of chemotherapy (cycle a and cycle b), and the wait-list control patients will crossover to the treatment arm at the beginning of his/her cycle b. fatigue will be measured using the revised piper fatigue scale along with quality of life measures. these study measures will be conducted at baseline, at the end of cycle a, and at the end of cycle b. we hypothesize that pranayama will improve clinical symptoms of fatigue and quality of life among patients undergoing chemotherapy.

Eligibility criteria:
inclusion criteria: * a diagnosis of cancer that requires at least 2 further cycles of chemotherapy on an every 14, 21, or 28 day schedule * a score of at least 4/10 on a 0-10 (0-none, 10-most) visual analog scale for fatigue at the time of enrollment * able to read, write and understand english * karnofsky performance status greater than 60 * ability to give informed consent exclusion criteria: * severe copd * receiving chronic oxygen therapy * congestive heart failure: nyha class 3 or greater * transfusion dependent anemia * uncontrolled thyroid disease * advance kidney disease requiring dialysis * advance liver disease * more than three previous chemotherapy regimens * current, ongoing yoga breathing practice

Keywords: fatigue chemotherapy yoga breathing cancer anxiety pranayama stress fatigue-associated symptoms in chemotherapy patients quality of life in chemotherapy patients
the proposed study aims to investigate the efficacy of quercetin as an adjunctive to mechanical debridement in treatment of periodontitis

Conditions: Periodontal Pocket

Summary: the proposed study aims to investigate the effect of quercetin in treatment of periodontitis patients

the proposed study aims to investigate the effect of quercetin in treatment of periodontitis patients not having systemic diseases.the 2ry aim of study to estimate the neacular factor kabba b level in gingival crevicular fluids.

Eligibility criteria:
inclusion criteria: - patients of both sexes with an age ranging between 25 and 55 years will be included in the study. patients diagnosed as having periodontitis based on clinical and radiographic examinations will be included exclusion criteria: * insulin dependent diabetes * thyroid disease * patients with sensitivity to the medication used in the study * patients with a history of antibiotic use or anti-inflammatory drugs during the previous 3 months prior to the study will be excluded from the study. * additionally, patients with systemic diseases, smokers, pregnant and lactating patients, and patients not compliant with oral hygiene procedures will also be excluded
pilot study of behavioral activation for prolonged grief

Conditions: Complicated Grief; Prolonged Grief Disorder; Major Depressive Disorder; Posttraumatic Stress Disorder

Summary: the institute of medicine identifies prolonged grief (pg) as a critical under-addressed public health problem for which are no empirically supported treatments. the purpose of this application is to pilot-test behavioral activation (ba) therapy for pg. ba is a well supported, stand alone intervention for depression and recently applied to posttraumatic stress disorder, which reduces rumination and avoidance behaviors that otherwise thwart access to natural rewarding contingencies and resources. the treatment focuses on promoting stable, active routines, self-care behaviors, enhanced self-efficacy, and reengagement with pleasurable activities and significant social resources. rumination, disengagement, and low self-efficacy are defining features of pg. further, in response to loss of intimates, the key factors that differentiate resilient people from those that have difficulties adapting is the maintenance or fast resumption of social and occupational functioning. thus, the main hypothesis of this study is that ba for pg will result in clinically significant reductions in rumination and functional disengagement. this is a preliminary small-scale pilot assessment of potential efficacy and feasibility of completing a large scale study of ba for pg.


Eligibility criteria:
inclusion criteria: * meet criteria for prolonged grief disorder * must be 21 years old or older * if taking psychotropic medication, must have been on a stable dose for three or more months prior to study entry exclusion criteria: * presence of active suicidal or homicidal ideation * a history of psychotic symptoms * current participation in psychosocial treatment focused on grief symptoms * active substance abuse

Keywords: behavior therapy bereavement complicated grief depression posttraumatic stress disorder
intraoral hypothermia device for preserving taste during radiation

Conditions: Head and Neck Cancer; Taste Dysfunction; Radiation Therapy

Summary: radiation therapy to the head and neck region is known to cause taste dysfunction. preliminary studies showed that cooling normal structures may lower damage caused by radiation. the purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatments to preserve or lower the decline of taste function.


Eligibility criteria:
inclusion criteria: * patients being treated with combination radiation therapy and chemotherapy (definitive) for locally advanced (ajcc 8th ct3-4 or cn+) squamous cell carcinoma of the larynx. * age ≥ 18. * eastern cooperative oncology group (ecog) performance status 0-1. * patients will engage in the informed consent process and provide study-specific informed consent prior to study entry and must be able to fill out toxicity and quality of life related questionnaires. * patients should be concurrently treated with any of the following chemotherapy drugs: cisplatin, carboplatin, and cetuximab. exclusion criteria: * patients receiving other forms of therapy intended to reduce taste dysfunction. * patients with metastatic disease. * patient with allergies or hypersensitivity to materials in the intraoral bolus. * patients who have received prior chemotherapy or radiation therapy for head and neck cancer. * patients who decline to use or cannot tolerate the intraoral device. * patients who are current or recent (within 3 months of treatment initiation) cigarette smokers. * patients who are unable to complete the required forms; however, verbal completion is adequate if recorded on the form daily. * patients with uncontrolled serious illness including, but not limited to, ongoing or serious active infection requiring iv antibiotics for over 30 days, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, immunocompromised state, significant hepatic insufficiency, significant hematological disease, and any serious or unstable psychological condition. * patients who are on any of the following medication that cannot find a suitable substitute during the study period: acetazolamide, maribavir (tak-620, phase 3 trial drug), eszopiclone, topiramate, captopril, lithium, procainamide, terbinafine, and amiodarone. * patients who have taste loss at baseline, assessed subjectively and objectively at the first encounter, will be excluded from the study and all analysis. they will be replaced with a new patient. * patients who have tested positive for covid-19 during the study period.